This is the text extract for How can Pharmaceutical Suppliers be involved in the Hospital Pharmaceutical Assessment Process (HPAP)? , browse documents here.

How can Pharmaceutical Suppliers be involved in the Hospital Pharmaceutical Assessment Process (HPAP)? The assessment process aims to encourage the exchanging of knowledge and views about the clinical and economic merits of new pharmaceuticals in order to reduce duplication of work, improve the consistency and quality of assessments, and improve consistency of access to pharmaceuticals. In order to achieve the aims of the process, supplier involvement is crucial in the following areas: 1. Suppliers need to notify PHARMAC of new hospital pharmaceuticals available, or which are likely to be available within the next year. Under Section 4.2.2 of the Hospital Strategy, pharmaceutical suppliers are required to submit applications to PHARMAC for the listing of pharmaceuticals in Section H (note that this includes Part III of Section H). For further information, please refer to the final version of the National Hospital Strategy (http://www.pharmac.govt.nz/pdf/nhps.pdf). 2. Suppliers can assist PHARMAC with assessments, and have an input into the process by completing this assessment template. 3. When PHARMAC has completed the draft analysis it is sent to DHBs and the supplier for comment. All comments are addressed or incorporated in the final version of the analysis. Suppliers are encouraged to send comments on the analysis to PHARMAC in order to have an influence on the final version that will be sent to DHBs and placed on Hospital Pharmaceutical Assessment Database (HPAD) website. The results of the analysis will also be included in Part III of Section H of the Pharmaceutical Schedule. Involvement in the HPAP has the following benefits: • input into PHARMAC’s assessment of the pharmaceutical; • wide circulation of information regarding the cost-benefit of a new pharmaceutical; • inclusion of a hospital pharmaceutical in Part III of Section H of the Pharmaceutical Schedule. For further information, please contact Rachel Grocott, Senior Hospital Pharmaceutical Analyst, at PHARMAC: rachel.grocott@pharmac.govt.nz; (04) 916 7535.

M16-3-12 #68962